Self‑collection for cervical screening
New at‑home self‑collection options for cervical samples are rolling out and labs are already warned to expect different adequacy and triage needs for self‑collected specimens. The Association for Diagnostics & Laboratory Medicine has published operational guidance on implementing self‑collected specimens, including regulatory and QA protocols labs must adopt. (kktv.com) (myadlm.org)
ADLM’s Clinical Laboratory News published operational guidance on March 1, 2026 outlining verification, regulatory and QA steps labs should follow before accepting self‑collected infectious‑disease or HPV specimens, authored by Allison Eberly, PhD. (myadlm.org) The FDA has cleared primary HPV testing on specified self‑collected vaginal sample combinations (Roche cobas with Copan or Evelyn brushes; BD Onclarity with Copan) after May 2024 test approvals, and an at‑home collection device (Teal Wand) received FDA clearance in May 2025 with the SELF‑CERV study reporting 96% detection of cervical precancer in trial comparisons. (clinician.com) Enduring Consensus/ASCCP recommendations published February 21, 2025 specify that a negative HPV result from a self‑collected vaginal specimen warrants repeat screening in 3 years, HPV16/18 positives should proceed to direct colposcopy with concurrent cytology, and other high‑risk positive patterns require a clinician‑collected cervical specimen for cytology or dual‑stain testing. (guidelinecentral.com) ADLM’s implementation checklist explicitly tells laboratories to engage clinical stakeholders, define expected test performance, turnaround time, projected volumes and staffing, and to perform method verification and stability studies—adding that at‑home collection raises additional concerns about specimen stability, transport conditions and temperature control. (myadlm.org) Because self‑collected samples are vaginal rather than directly cervical, they frequently cannot support reflex cytology from the same specimen; guidance and clinician communication tools note roughly one in ten screening tests may be HPV‑positive and therefore require a follow‑up speculum exam and clinician‑collected sample for cytology to complete triage. (asccp.org) Commercial laboratory rollout is already underway: Quest Diagnostics announced an FDA‑cleared self‑collection HPV solution in April 2025 for use in offices and planned expansion to its ~2,000 U.S. patient service centers, and high‑throughput platforms such as Roche’s cobas systems (cobas 4800/5800/6800/8800) are positioned to process large volumes once workflows and verifications are in place. (prnewswire.com) Federal policy changes include HRSA’s January 5, 2026 update that designates high‑risk HPV testing (clinician‑ or self‑collected) as the preferred screening modality for average‑risk women ages 30–65 and notes updated screening guideline coverage will take effect for most health plans starting in 2027. (hhs.gov)
